SATT AxLR enters the capital of Aceso Therapeutics and supports the development of ACT-101 for cystic fibrosis
Montpellier, March 2026 — Aceso Therapeutics announces the entry of SATT AxLR into its capital, marking a new milestone in the development of its biotech focused on innovative therapies for cystic fibrosis.
This support confirms the maturity of the ACT-101 program, an antisense oligonucleotide (ASO)-based therapy currently in advanced preclinical development, with an IND filing planned for 2027 (TRL 6).
After supporting the maturation of the project up to TRL 4, SATT AxLR confirms its commitment within the framework of this technology transfer, as well as its role in management and valorization on behalf of the relevant Montpellier research institutions, including the Université de Montpellier, INSERM, and CNRS.
Cystic fibrosis remains a rare genetic disease affecting more than 110,000 patients worldwide, of whom approximately 20% still have no effective therapeutic option. ACT-101 aims to address this unmet medical need by targeting the underlying genetic mechanisms of the disease.
This transaction is part of an innovation ecosystem supported by public research institutions, the Occitanie region, and Bpifrance, fostering technology transfer and value creation in the biotechnology sector.
Contact press : contact@aceso-therapeutics.com
Linkedin: https://www.linkedin.com/company/aceso-therapeutics